OBJECTIVES: Gemcitabine is a potent radiosensitizer. When combined with standard radiotherapy (XRT) the gemcitabine dose must be reduced to about 10% of its conventional dose. Oxaliplatin and erlotinib also have radiosensitizing properties. Oxaliplatin and gemcitabine have demonstrated synergy in vitro. We aimed to determine the maximum tolerated dose of oxaliplatin and gemcitabine with concurrent XRT, then oxaliplatin, gemcitaibine, and erlotinib with XRT in the treatment of locally advanced and low-volume metastatic pancreatic or biliary cancer. METHODS: A modified 3+3 dose-escalation design was used for testing 4 dose levels of oxaliplatin and gemcitabine given once weekly for a maximum of 6 weeks with daily XRT in fractions of 1.8 Gy to a total dose of 50.4 Gy. Dose-limiting toxicity (DLT) was defined as any grade 4 toxicity or grade 3 toxicity resulting in a treatment delay of >1 week. In addition, dose reduction in 2 of the 3 patients in a given cohort was counted as a DLT in dose escalation-deescalation rule in the modified 3+3 design. RESULTS: Eighteen patients were enrolled, all with pancreatic cancer. Grade 4 transaminitis in a patient in cohort 3 resulted in cohort expansion. Cohort 4, the highest planned dose cohort, had no DLTs. The recommended phase II dose is oxaliplatin 50 mg/m(2)/wk with gemcitabine 200 mg/m(2)/wk and 50.4 Gy XRT. The most prevalent grade 3 toxicities were nausea (22%), elevated transaminases (17%), leucopenia (17%), and hyperglycemia (17%). Median progression-free survival was 7.1 months (95% confidence interval, 4.6-11.1 mo) and median overall survival was 10.8 months (95% confidence interval, 7.1-16.7 mo). The addition of erlotinib was poorly tolerated at the first planned dose level, but full study of the combination was hindered by early closure of the study. CONCLUSIONS: Weekly oxaliplatin 50 mg/m/wk combined with gemcitabine 200 mg/m/wk and XRT for pancreatic cancer has acceptable toxicity and interesting activity.
OBJECTIVES:Gemcitabine is a potent radiosensitizer. When combined with standard radiotherapy (XRT) the gemcitabine dose must be reduced to about 10% of its conventional dose. Oxaliplatin and erlotinib also have radiosensitizing properties. Oxaliplatin and gemcitabine have demonstrated synergy in vitro. We aimed to determine the maximum tolerated dose of oxaliplatin and gemcitabine with concurrent XRT, then oxaliplatin, gemcitaibine, and erlotinib with XRT in the treatment of locally advanced and low-volume metastatic pancreatic or biliary cancer. METHODS: A modified 3+3 dose-escalation design was used for testing 4 dose levels of oxaliplatin and gemcitabine given once weekly for a maximum of 6 weeks with daily XRT in fractions of 1.8 Gy to a total dose of 50.4 Gy. Dose-limiting toxicity (DLT) was defined as any grade 4 toxicity or grade 3 toxicity resulting in a treatment delay of >1 week. In addition, dose reduction in 2 of the 3 patients in a given cohort was counted as a DLT in dose escalation-deescalation rule in the modified 3+3 design. RESULTS: Eighteen patients were enrolled, all with pancreatic cancer. Grade 4 transaminitis in a patient in cohort 3 resulted in cohort expansion. Cohort 4, the highest planned dose cohort, had no DLTs. The recommended phase II dose is oxaliplatin 50 mg/m(2)/wk with gemcitabine 200 mg/m(2)/wk and 50.4 Gy XRT. The most prevalent grade 3 toxicities were nausea (22%), elevated transaminases (17%), leucopenia (17%), and hyperglycemia (17%). Median progression-free survival was 7.1 months (95% confidence interval, 4.6-11.1 mo) and median overall survival was 10.8 months (95% confidence interval, 7.1-16.7 mo). The addition of erlotinib was poorly tolerated at the first planned dose level, but full study of the combination was hindered by early closure of the study. CONCLUSIONS: Weekly oxaliplatin 50 mg/m/wk combined with gemcitabine 200 mg/m/wk and XRT for pancreatic cancer has acceptable toxicity and interesting activity.
Authors: Andrew H Ko; Elizabeth Dito; Brian Schillinger; Alan P Venook; Emily K Bergsland; Margaret A Tempero Journal: J Clin Oncol Date: 2005-12-12 Impact factor: 44.544
Authors: James D Murphy; Saroja Adusumilli; Kent A Griffith; Michael E Ray; Mark M Zalupski; Theodore S Lawrence; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-26 Impact factor: 7.038
Authors: David Iannitti; Tom Dipetrillo; Paul Akerman; John Mark Barnett; Christine Maia-Acuna; Dennis Cruff; Tom Miner; Diane Martel; William Cioffi; Melissa Remis; Teresa Kennedy; Howard Safran Journal: Am J Clin Oncol Date: 2005-12 Impact factor: 2.339
Authors: C Louvet; T André; G Lledo; P Hammel; H Bleiberg; C Bouleuc; E Gamelin; M Flesch; E Cvitkovic; A de Gramont Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: A Duffy; J Kortmansky; G K Schwartz; M Capanu; S Puleio; B Minsky; L Saltz; D P Kelsen; E M O'Reilly Journal: Ann Oncol Date: 2007-09-17 Impact factor: 32.976
Authors: Sameer P Desai; Edgar Ben-Josef; Daniel P Normolle; Isaac R Francis; Joel K Greenson; Diane M Simeone; Alfred E Chang; Lisa M Colletti; Theodore S Lawrence; Mark M Zalupski Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: A William Blackstock; Joel E Tepper; Donna Niedwiecki; Donna R Hollis; Robert J Mayer; Margaret A Tempero Journal: Int J Gastrointest Cancer Date: 2003
Authors: D Mavroudis; P Pappas; C Kouroussis; S Kakolyris; S Agelaki; K Kalbakis; N Androulakis; J Souglakos; N Vardakis; M Nikolaidou; G Samonis; M Marselos; V Georgoulias Journal: Ann Oncol Date: 2003-02 Impact factor: 32.976
Authors: A Moschidis; A Papageorgiou; K Atmatzidis; K Tsalis; E Moschidis; J Livanis; E Chrysogelou; D Mourelatos; D Tsavdaridis; N Harlaftis Journal: Chemotherapy Date: 2007-03-07 Impact factor: 2.544
Authors: Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang Journal: Ther Innov Regul Sci Date: 2014-01 Impact factor: 1.778